findmyKOL
Clinical trialNCT02049294CompletedPhase 2/PHASE3Interventional

Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis

SponsorMcMaster UniversityEnrollment11Eosinophilic BronchitisSteroid and/or Prednisone Dependent Asthma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Richard Leigh

    Calgary, Alberta, Canada

  • University of British Columbia

    Vancouver, British Columbia, Canada

  • Mcmaster University

    Hamilton, Ontario, Canada

  • University of Laval

    Laval, Quebec, Canada

  • University of Montreal

    Montreal, Quebec, Canada

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Mar 2014
Primary completion
30 Sept 2017
Completion
30 Sept 2017
Last update posted
4 Apr 2018
Registered enrollment
11
Registry id
NCT02049294

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.